Personalized cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT06304636
Summary
This early-stage study tested the safety of a personalized cell therapy called Descartes-15 for patients with advanced multiple myeloma that has returned or stopped responding to other treatments. The therapy involves modifying a patient's own immune cells to target the cancer. The study was small and ended early, focusing primarily on determining safe dosage levels rather than proving effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Cancer and Blood Disorders (AON)
Bethesda, Maryland, 20817, United States
Conditions
Explore the condition pages connected to this study.